LONG MINI-FUTURE - GENMAB | Market Closed - Deutsche Boerse AG 18:55:10 28/06/2024 BST | ||
| 7.89 EUR | -7.07% |
|
| Current month | -24.79% | ||
| 1 month | -23.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 7.89 | -7.07% |
| 27/06/24 | 8.49 | -0.35% |
| 26/06/24 | 8.52 | +0.95% |
| 25/06/24 | 8.44 | -0.59% |
| 24/06/24 | 8.49 | -1.05% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 06:55 pm
More quotesStatic data
| Product type | Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VF21XB |
| ISIN | DE000VF21XB6 |
| Date issued | 13/02/2019 |
| Strike | 1,153 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.76 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 30.58 € |
|---|---|
| Lowest since issue | 0.81 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,745
DKK
Average target price
2,464
DKK
Spread / Average Target
+41.20%
- Stock Market
- Certificates
- Certificat
